Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial

Kim CY, et al.: J Neurooncol. 2020 Feb;146（3）:399-406. doi: 10.1007/s11060-019-03361-2.

Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial

Toms SA, et al.: J Neurooncol. 2019 Jan;141（2）:467-473. doi: 10.1007/s11060-018-03057-z.

Efficacy and Safety of Tumor Treating Fields （TTFields） in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial

Ram Z, et al.: Front Oncol. 2021 Sep 27;11:671972. doi: 10.3389/fonc.2021.671972. eCollection 2021.